Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Reveal Bradycardiac Effects Caused by Co-Administration of Sofosbuvir and Amiodarone

Assay and Drug Development Technologies
Yankun YuYing Xu

Abstract

Co-administration of sofosbuvir, an anti-hepatitis C virus medication, and antiarrhythmic amiodarone causes symptomatic severe bradycardia in patients and animal models. However, in a few in vitro studies, the combination of sofosbuvir and amiodarone resulted in tachycardiac effects in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). This discrepancy may be attributable to the use of immature hiPSC-CMs in the in vitro studies. To address this, we evaluated the ability of our in-house hiPSC-CMs to assess the interactions between sofosbuvir and amiodarone in vitro. We performed whole-cell patch recordings on hiPSC-CMs to examine the cardiac effect of sofosbuvir and amiodarone, alone or in combination. We found that sofosbuvir and amiodarone caused bradycardiac effects (the beating rate decreased to 75% of the vehicle control, P < 0.001) on our hiPSC-CMs when applied in combination, but they had no significant effect when applied alone. Furthermore, the bradycardiac effect was membrane potential dependent: it increased with depolarization. This raised the possibility that the bradycardiac effects in vivo may originate in nodal cells, which have a more depolarized resting membrane potential compared with vent...Continue Reading

References

Mar 1, 1984·Clinical Pharmacokinetics·R LatiniR E Kates
Dec 1, 1996·Journal of Cardiac Failure·J ToyamaI Kodama
Jun 23, 2011·Toxicological Sciences : an Official Journal of the Society of Toxicology·Liang GuoKyle L Kolaja
May 22, 2013·Toxicological Sciences : an Official Journal of the Society of Toxicology·Kate HarrisArun Sridhar
Sep 21, 2013·Toxicological Sciences : an Official Journal of the Society of Toxicology·Liang GuoKyle L Kolaja
Sep 24, 2013·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Glenna C L BettRandall L Rasmusson
Jan 3, 2015·Expert Opinion on Drug Metabolism & Toxicology·Vincent SorianoJosé M Peña
Oct 22, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Christopher P ReganFrederick J Sannajust
Aug 3, 2016·Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology·Mohammed El Amine Ghembaza, Ali Lounici
Oct 30, 2016·Toxicological Sciences : an Official Journal of the Society of Toxicology·Daniel C MillardJames D Ross
Oct 11, 2017·Biochemical and Biophysical Research Communications·Patrick K W ChanRonald A Li

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Software Mentioned

Clampfit
Patchmaster
GraphPad ( Prism

Related Concepts

Related Feeds

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.